SCHEMBL29660346

SCHEMBL29660346

C=CCc1sc(-c2ccc(OCC)cc2)nc1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TP53 P04637 3/20 0.38
HSD17B10 Q99714 3/20 0.38
NPC1 O15118 1/20 0.38
ALPL P05186 1/20 0.37
ALPI P09923 1/20 0.37
PPARA Q07869 3/20 0.37
PTPN11 Q06124 1/20 0.37
LMNA P02545 1/20 0.36
THRB P10828 1/20 0.36
PPARD Q03181 2/20 0.36
PPARG P37231 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29660324 0.81 MAPT (0.42) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL29660317 0.81 PTPN11 (0.44) MAPTL3MBTL1MEN1KMT2AKDM4E
SCHEMBL29660409 0.80 MAPT (0.46) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL29660340 0.79 MAPT (0.40) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL29660360 0.79 TARBP2 (0.41) MAPTL3MBTL1MEN1KMT2AKDM4E
SCHEMBL29660334 0.77 TARBP2 (0.44) MAPTL3MBTL1MEN1KMT2AKDM4E
SCHEMBL29660299 0.77 HSD17B10 (0.40) MAPTL3MBTL1MEN1KMT2AKDM4E
SCHEMBL29911091 0.76 MAPT (0.41) MAPTL3MBTL1MEN1KMT2AKDM4E
SCHEMBL29660337 0.76 KDM4E (0.42) MAPTL3MBTL1MEN1KMT2AKDM4E
SCHEMBL29911121 0.75 L3MBTL1 (0.57) MAPTL3MBTL1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289698-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-09-15 US disclosed
EP-4003955-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289698-A1 INHIBITORS OF HUMAN ATGL LIPC, LIPG, PNLIP MAPT 2152/4885L3MBTL1 268/4885MEN1 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.